Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

438
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
438
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

70
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
70
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

27
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
27
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

15
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
15

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The diving reflex elicits potent, non-electrophilic Nrf2 activation via trigeminal CGRP signaling.

Free radical biology & medicine·2026
Same author

Human Ghrelin Improves Vascular Integrity and Survival After Total Body Irradiation.

Cells·2026
Same author

Radiation-induced eCIRP Causes Alzheimer's Disease-like Neuronal Tau Phosphorylation.

Molecular neurobiology·2026
Same author

Retraction notice to "Extracellular cold-inducible RNA-binding protein regulates neutrophil extracellular trap formation and tissue damage in acute pancreatitis" Lab Invest 2020 Dec;100(12):1618-1630.

Laboratory investigation; a journal of technical methods and pathology·2026
Same author

Extracellular CIRP augments inflammation in acute kidney injury via NKG2D-positive macrophages.

Frontiers in immunology·2026
Same author

Ghrelin mitigates partial body irradiation-induced gastrointestinal acute radiation syndrome by promoting intestinal stem cell regeneration.

Molecular medicine (Cambridge, Mass.)·2025

Related Experiment Video

Updated: Sep 5, 2025

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
07:30

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

10.1K

TREM-1 Modulation Strategies for Sepsis.

Sara Siskind1,2,3, Max Brenner1,2,3, Ping Wang1,2,3

  • 1Center for Immunology and Inflammation, The Feinstein Institutes for Medical Research, Manhasset, NY, United States.

Frontiers in Immunology
|July 5, 2022
PubMed
Summary

Triggering receptor expressed on myeloid cells-1 (TREM-1) amplifies inflammation in sepsis, increasing mortality. Inhibiting TREM-1 shows promise as a therapeutic strategy for sepsis and septic shock.

Keywords:
DAMPTREM-1inflammationsepsisshock

More Related Videos

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats
05:56

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats

Published on: February 20, 2021

2.1K
A Data-Driven Approach to Quantifying Immune States in Sepsis
07:42

A Data-Driven Approach to Quantifying Immune States in Sepsis

Published on: February 7, 2025

310

Related Experiment Videos

Last Updated: Sep 5, 2025

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
07:30

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

10.1K
A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats
05:56

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats

Published on: February 20, 2021

2.1K
A Data-Driven Approach to Quantifying Immune States in Sepsis
07:42

A Data-Driven Approach to Quantifying Immune States in Sepsis

Published on: February 7, 2025

310

Area of Science:

  • Immunology
  • Pathophysiology
  • Pharmacology

Background:

  • Triggering receptor expressed on myeloid cells-1 (TREM-1) is a pattern recognition receptor that amplifies immune responses.
  • TREM-1 upregulation in inflammatory diseases, particularly sepsis, contributes to dysregulated immune responses and increased mortality.
  • Elevated TREM-1 expression on immune cells and soluble TREM-1 (sTREM-1) levels are observed in septic patients.

Purpose of the Study:

  • To review endogenous ligands investigated as activators of TREM-1.
  • To highlight the development and efficacy of novel TREM-1 inhibitors for sepsis treatment.
  • To explore TREM-1 modulation as a therapeutic strategy for sepsis and septic shock.

Main Methods:

  • Literature review of studies on TREM-1 ligands and inhibitors.
  • Analysis of TREM-1 expression and sTREM-1 levels in sepsis.
  • Evaluation of the efficacy of TREM-1 inhibitory peptides.

Main Results:

  • TREM-1 activation leads to increased pro-inflammatory cytokine and chemokine release.
  • Elevated TREM-1 and sTREM-1 levels correlate with sepsis severity and mortality.
  • Various endogenous ligands for TREM-1 have been identified.
  • Novel TREM-1 inhibitors demonstrate potential in preclinical models of sepsis.

Conclusions:

  • TREM-1 plays a critical role in amplifying the inflammatory cascade during sepsis.
  • Targeting TREM-1 with inhibitors represents a promising therapeutic avenue for sepsis and septic shock.
  • Further research into TREM-1 ligands and inhibitors is warranted for clinical translation.